Chemed (NYSE:CHE)‘s stock had its “hold” rating restated by analysts at Royal Bank of Canada in a research note issued to investors on Friday. They presently have a $258.00 price objective on the stock. Royal Bank of Canada’s price target indicates a potential upside of 1.35% from the company’s previous close.
Several other equities analysts have also weighed in on CHE. TheStreet raised Chemed from a “c+” rating to an “a-” rating in a research note on Friday, October 27th. KeyCorp reaffirmed a “hold” rating on shares of Chemed in a research note on Friday, October 27th. ValuEngine lowered Chemed from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Zacks Investment Research raised Chemed from a “hold” rating to a “buy” rating and set a $251.00 price objective on the stock in a research note on Thursday, November 2nd. Finally, Oppenheimer lifted their price objective on Chemed from $220.00 to $225.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $261.33.
Chemed (NYSE:CHE) opened at $254.56 on Friday. The firm has a market capitalization of $4,064.30, a PE ratio of 28.73 and a beta of 1.13. Chemed has a 52 week low of $170.69 and a 52 week high of $275.83. The company has a quick ratio of 0.48, a current ratio of 0.91 and a debt-to-equity ratio of 0.17.
In related news, VP Naomi C. Dallob sold 950 shares of the business’s stock in a transaction that occurred on Monday, November 27th. The stock was sold at an average price of $240.38, for a total transaction of $228,361.00. Following the transaction, the vice president now directly owns 9,747 shares of the company’s stock, valued at approximately $2,342,983.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Michael D. Witzeman sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $250.00, for a total value of $250,000.00. Following the transaction, the vice president now directly owns 3,334 shares in the company, valued at $833,500. The disclosure for this sale can be found here. Insiders have sold a total of 13,950 shares of company stock worth $3,370,681 over the last three months. 4.90% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in CHE. Royal Bank of Canada lifted its position in Chemed by 17.2% during the 2nd quarter. Royal Bank of Canada now owns 8,008 shares of the company’s stock worth $1,638,000 after acquiring an additional 1,176 shares in the last quarter. State Street Corp lifted its position in Chemed by 1.8% during the 2nd quarter. State Street Corp now owns 453,605 shares of the company’s stock worth $92,782,000 after acquiring an additional 8,238 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in Chemed during the 2nd quarter worth approximately $354,000. Arrowstreet Capital Limited Partnership acquired a new position in Chemed during the 2nd quarter worth approximately $941,000. Finally, USA Financial Portformulas Corp acquired a new position in Chemed during the 2nd quarter worth approximately $292,000. 97.04% of the stock is currently owned by hedge funds and other institutional investors.
Chemed Company Profile
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.